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continuous combination prescriptions (subgroup) from a managed care organization 
health care system perspective. METHODS: Using the Integrated Health Care Infor-
mation Services National Managed Care Benchmark Database from January 19997-
June 2007, we followed newly-diagnosed, HCV-infected patients with cirrhosis for 
the occurrence of end-staged liver diseases (ESLD), starting from the date of their 
ﬁrst prescriptions. For each patient, we measured effectiveness (Ei) as time to ESLD 
occurrence or censored, and costs (Ci) as the sum of pharmacy, outpatient and 
inpatient costs incurred in the follow up (2007 US dollars). Individual patient’s net 
beneﬁt was calculated as lambda times Ei minus Ci, and the net beneﬁt regression 
framework was employed to determine the cost-effectiveness of antiviral therapy and 
the importance of covariates on the incremental net beneﬁt of an intervention control-
ling for patient-related characteristics. The inverse probability of censored weighting 
technique was used to account for potential bias due to censored cost and effectiveness 
data. RESULTS: The results found that, at a number of lambda values qUS$10,000, 
combination antiviral therapy was more cost effective than no treatment in base case 
analysis. In subgroup analysis, continuous antiviral therapy was cost effective than 
no treatment at lambda value qUS$1000,000. Time of HCV diagnosis, HIV co-infec-
tion and prior gastroenterologist visits were potentially important covariates on 
the incremental net beneﬁt of treatment. CONCLUSIONS: From the standpoint of 
cost-effectiveness, continuation of antiviral therapy should consider the variability 
in early viral response because treatment beyond 12 weeks is no recommended 
for genotype 1, HCV-infected patients when achieving sustained viral response is 
unlikely.
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OBJECTIVES: To evaluate long-term cost-effectiveness of the treatment of CHB 
HBeAg-positive and -negative patients with telbivudine compared with lamivudine. 
METHODS: The study was conducted from China’s social health insurance perspec-
tive over a lifetime horizon using a Markov model. Individual patient data (age, 
gender, virological, serological and biochemical response and resistance to telbivudine 
versus lamivudine) after 104 weeks from the multinational GLOBE registration trial 
were applied. Disease progression from CHB to other health states was derived from 
literature. Economic outcomes, including China-speciﬁc data for life expectancy, 
utility and drug costs were applied. The annual medical expenditure was calculated 
with 599 community patients with CHB-related diseases in Beijing and Guangzhou 
cities of China and data were also retrieved from literature. Drug treatment of telbi-
vudine or lamivudine treatment is ceased upon achieving chronic hepatitis HBeAg-, 
HBsAg-. All costs were valued in Chinese-yuan, year 2007 values. Costs and outcomes 
were discounted at 3% per annum. Sensitivity analysis was conducted to evaluate 
uncertainty in study results. RESULTS: Compared with lamivudine, the incremental 
cost for 1 additional QALY gained with telbivudine in treating HBeAg-positive and 
-negative CHB were 13,361 yuan (US$1,965) and 62,999 yuan (US$9,265) in Beijing, 
as well 12,078 yuan (US$1,776) and 65,864 yuan (US$9,686) in Guangzhou, respec-
tively. According to national economic burden of CHB-related diseases retrieved from 
literature, the ICER with telbivudine vs lamivudine were 3,170 yuan (US$466) and 
70,420 yuan (US$10,356) for HBeAg-positive and -negative CHB, respectively. CON-
CLUSIONS: Among CHB patients, treatment with telbivudine is cost effective as 
compared to lamivudine, based on the World Health Organization’s recommended 
maximum willingness to pay threshold.
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OBJECTIVES: Rotavirus (RV) is a major cause of gastroenteritis (GE) in infants but 
can be prevented by vaccination. The study objective was to estimate the cost effective-
ness of universal rotavirus vaccination of infants from an Irish Healthcare payer per-
spective. METHODS: A published Markov model, calibrated to observed Irish 
epidemiological data was used. A cohort of 70,600 newborns was followed over ﬁve 
years during which the seasonality of infection and protective effects of breastfeeding 
were captured. Routine vaccination with the oral 2- dose vaccine RIX 4414 was 
compared with no vaccination. Efﬁcacy from a European phase-III trial (102247) 
showed 96% and 86% against severe RVGE and 100% and 92% against hospitalisa-
tions due to RV in the ﬁrst and second years post vaccination respectively. Costs were 
from published sources in 2007 prices. Utilities came from a UK study of physician 
scores using the EQ-5D questionnaire. Costs and effects, discounted at 3.5%, were 
assessed over lifetime. Sensitivity analyses were conducted. RESULTS: The model 
estimated that 14,700 GP visits, 4,000 A&E visits, 3,400 hospitalisations and 840 
nosocomial cases occurred in the birth cohort at a cost of a7.3m. With a coverage 
rate of 87% the number of GP and hospital visits could be reduced by 82% with 
vaccination. Cost effectiveness was estimated at a29,398 per QALY. These results 
were driven by the high rate of hospitalisation due to RV. The results were most sensi-
tive to the cost of vaccination and hospitalisations, incidence of RV and hospitalisa-
tions and the discount rate. CONCLUSIONS: Rotavirus imposes a signiﬁcant ﬁnancial 
burden on the Irish health care system. Universal vaccination of infants is a cost-
 effective approach to reducing this burden.
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OBJECTIVES: To estimate the clinical and economic impact of vaccinating a birth 
cohort with the newly licensed 10-valent pneumococcal non-typeable haemophilus 
inﬂuenzae protein-D conjugate vaccine (PHiD-CV) compared with the 13-valent pneu-
mococcal candidate vaccine (PCV-13) over lifetime. METHODS: We developed an 
age-compartmental, deterministic, and static Markov model to project the impact of 
pneumococcal vaccination on the incidence of pneumococcal infections from birth 
through lifetime in speciﬁc age–time units (months). The disease types modeled include 
invasive pneumococcal disease (IPD), community acquired pneumonia (CAP) and 
acute otitis media (AOM), assuming 11 health states per condition. Serotype distribu-
tions per disease type and age group were incorporated. Costs, health gains and cost-
effectiveness were estimated. A 4-dose (31) schedule is assumed for both vaccines 
with 100% vaccine coverage. All analyses were performed from the Canadian health 
care system perspective assuming a price parity of $70 per dose. The model uses 
Canada speciﬁc epidemiological data. Both outcomes and cost were discounted at 
3.5%. Various sensitivity analyses were performed to assess the impact of changes in 
the key assumptions of the model. RESULTS: Compared with PCV-13, vaccinating a 
birth cohort of 340,000 with PHiD-CV in Canada is expected to prevent 92,026 
additional AOM myringotomies and 108,978 ambulatory visits due to AOM over 
lifetime. The impact of the two vaccines on IPD is projected to be comparable. At 
price parity of $70 per dose, the total savings to the Canadian health care system over 
the lifetime of the cohort is projected to be $58.7M for PHiD-CV compared to PCV-
13. Sensitivity analyses indicate that AOM and bacteraemia have the biggest impact 
on the model. CONCLUSIONS: Overall, the clinical beneﬁts of the two vaccines are 
comparable on IPD. QALYs are improved for PHiD-CV compared to PCV-13 because 
of the greater impact on AOM. PHiD-CV is projected to be cost-saving to the Cana-
dian health care system compared to PCV-13.
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OBJECTIVES: To determine the cost-effectiveness of pneumococcal non-typeable 
Haemophilus inﬂuenzae protein-D conjugate vaccine (PHiD-CV) when compared with 
7-valent pneumococcal conjugate vaccine (PCV-7) and with no vaccination for the 
prophylaxis of invasive (ID) and non-invasive pneumococcal diseases in Poland. 
METHODS: A Markov cohort model was used with a starting birth cohort of 393 
506 infants. The Streptococcus pneumoniae serotype distribution from Czech Repub-
lic setting was selected as a proxy for Polish data. The effectiveness and safety data 
came from a meta-analysis of clinical trial results. Limited cross-protection of sero-
types 6A and 19A, herd protection and serotype replacement were included into the 
model design. Ten years time horizon (the period of direct vaccine effect) and 96% 
vaccine coverage rate were considered. Direct medical costs were collected during 
January-March, 2009 from a public payer’s and patient’s perspective. Price parity 
between vaccines was assumed. Sensitivity analysis was carried out. Annual discount 
rate for cost and effect was 5.0% and 3.5% respectively. RESULTS: Base-case analysis 
of PHiD-CV shows that mass vaccination of the birth cohort reduced the number of 
ID by 120, pneumonia by 17,102, and acute otitis media events by 113,768 cases over 
10 years. When compared with PCV-7 and no vaccination, PHiD-CV offered a Quality 
Adjusted Life Year gain (QALY) of 0.0045 and 0.0068 per vaccinated child respec-
tively. Prophylaxis with PHiD-CV instead of PCV-7 induced cost savings of 39.97 PLN 
per child. Vaccination with PHiD-CV dominated PCV-7 but when compared with no 
vaccination an incremental cost per QALY was estimated at 54,549 PLN. Sensitivity 
analysis showed consistency in the results. A few analysis limitations were identiﬁed 
such as length of vaccine protection and reliable serotype distribution data. CONCLU-
SIONS: Compared with no vaccination the model indicates that PHiD-CV is cost-
effective in Poland and has superior economic proﬁle to PCV-7.
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OBJECTIVES: National 7-valent pneumococcal vaccination (PCV7) was introduced 
in Greece in 2006. In May 2009 a 10-valent (PCV10) vaccine became available. A 
13-valent (PCV13) vaccine is expected in late 2009. This study aims to assess the 
clinical and economic beneﬁts of national immunization with PCV13 compared to 
PCV7 and PCV10 from the national health system perspective. METHODS: Using an 
